Omeros
Omeros
OMER
NASDAQ
4.21
USD
-52.38%
About
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders.
Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial.
OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 204.8K |
| Three Month Average Volume | 7.9M |
| High Low | |
| Fifty-Two Week High | 5.68 USD |
| Fifty-Two Week Low | 0.92 USD |
| Fifty-Two Week High Date | 24 Jul 2024 |
| Fifty-Two Week Low Date | 16 Oct 2023 |
| Price and Volume | |
| Current Price | 4.21 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -18.17% |
| Thirteen Week Relative Price Change | 17.07% |
| Twenty-Six Week Relative Price Change | -19.90% |
| Fifty-Two Week Relative Price Change | -2.90% |
| Year-to-Date Relative Price Change | 8.72% |
| Price Change | |
| One Day Price Change | 3.44% |
| Thirteen Week Price Change | 25.30% |
| Twenty-Six Week Price Change | -11.92% |
| Five Day Price Change | -0.71% |
| Fifty-Two Week Price Change | 21.68% |
| Year-to-Date Price Change | 28.75% |
| Month-to-Date Price Change | -21.89% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -0.4087 USD |
| Book Value Per Share (Most Recent Quarter) | -2.15031 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.4087 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -2.15031 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -3.06228 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.78805 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -3.32074 USD |
| Normalized (Last Fiscal Year) | -2.85359 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.78805 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -3.32074 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.87782 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.34534 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.81125 USD |
| Cash Per Share (Most Recent Quarter) | 2.7425 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.77338 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -3.29049 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.5703 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -5.56% |
| Total Debt (5 Year) | 17.53% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -59.45% |
| EPS Change (Trailing Twelve Months) | -12.81% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | 3 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 264.2M |
| Net Debt (Last Fiscal Year) | 167.7M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 4 |
| Current Ratio (Most Recent Quarter) | 3 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | 74.3M |
| Free Cash Flow (Trailing Twelve Months) | -155,526,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -5 |
| Net Interest Coverage (Trailing Twelve Months) | -6 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -36.09% |
| Return on Assets (Trailing Twelve Months) | -45.24% |
| Return on Assets (5 Year) | -55.51% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -576.33% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -44.88% |
| Return on Investment (Trailing Twelve Months) | -58.74% |
| Return on Investment (5 Year) | -70.10% |